Organon & Co. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| ($ in millions and shares in thousands, except per share amounts) | 2025 | 2024 | 2023 | ||||||||||||||
| Net income | $ | 187 | $ | 864 | $ | 1,023 | |||||||||||
| Basic weighted average number of shares outstanding | 259,495 | 257,046 | 255,239 | ||||||||||||||
| Stock awards and equity units (share equivalent) | 1,269 | 2,106 | 1,031 | ||||||||||||||
| Diluted weighted average common shares outstanding | 260,764 | 259,152 | 256,270 | ||||||||||||||
| EPS: | |||||||||||||||||
| Basic | $ | 0.72 | $ | 3.36 | $ | 4.01 | |||||||||||
| Diluted | $ | 0.72 | $ | 3.33 | $ | 3.99 | |||||||||||
| Anti-dilutive shares excluded from the calculation of EPS | 12,641 | 8,363 | 9,025 | ||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
| 2023 | Feb 26, 2024 | |
| 2022 | Feb 27, 2023 | |
| 2021 | Mar 21, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.